Insmed (INSM) Inventory Average (2019 - 2026)
Insmed (INSM) posted quarterly Inventory Average of $132.5 million for Q1 2026, up 32.96% year-over-year from $99.6 million in Q1 2025, and up 4.72% quarter-over-quarter from $126.5 million in Q4 2025.
Insmed (INSM) Inventory Average (2019 - 2026) Analysis & Trends
Insmed's Inventory Average history runs 8 years deep, the most recent figure standing at $132.5 million for Q1 2026.
- In Q1 2026, Inventory Average rose 32.96% year-over-year to $132.5 million; the TTM figure through Mar 2026 stood at $132.5 million (up 32.96% YoY), while the FY2025 annual figure was $115.3 million, up 26.85% from the prior year.
- Inventory Average for Q1 2026 stood at $132.5 million, up from $126.5 million in the prior quarter.
- The five-year high for Inventory Average was $132.5 million in Q1 2026, with the low at $65.6 million in Q1 2022.
- The 5-year median for Inventory Average is $83.1 million (2024), against an average of $88.7 million.
- The sharpest annual moves came in 2022 and 2026: Inventory Average increased 1.29% in 2022, then jumped 32.96% in 2026.
- Insmed's Inventory Average stood at $68.1 million in 2022, then climbed by 18.34% to $80.6 million in 2023, then rose by 22.26% to $98.5 million in 2024, then climbed by 28.41% to $126.5 million in 2025, then rose by 4.72% to $132.5 million in 2026.
- Business Quant data shows INSM's Inventory Average at $132.5 million in Q1 2026, $126.5 million in Q4 2025, and $114.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.09 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 707.10 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 355,998.06 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 90.57 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 137.65 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 137.65 Mn |
| Mar 31, 2026 | 132.49 Mn |
| Dec 31, 2025 | 126.52 Mn |
| Sep 30, 2025 | 114.29 Mn |
| Jun 30, 2025 | 104.16 Mn |
| Mar 31, 2025 | 99.65 Mn |
| Dec 31, 2024 | 98.52 Mn |
| Sep 30, 2024 | 94.27 Mn |
| Jun 30, 2024 | 86.51 Mn |
| Mar 31, 2024 | 83.10 Mn |
| Dec 31, 2023 | 80.59 Mn |
| Sep 30, 2023 | 77.64 Mn |
| Jun 30, 2023 | 74.33 Mn |
| Mar 31, 2023 | 70.62 Mn |
| Dec 31, 2022 | 68.10 Mn |
| Sep 30, 2022 | 66.65 Mn |
| Jun 30, 2022 | 65.58 Mn |
| Mar 31, 2022 | 65.58 Mn |
| Dec 31, 2021 | 67.23 Mn |
| Sep 30, 2021 | 63.92 Mn |